The effects of levamisole on experimental endometriosis: a randomized controlled trial in a rat model

Purpose To assess the effects of levamisole on experimental endometriosis in rats through the histopathology of the implants, the blood leukocyte and lymphocyte counts and the concentrations of interleukin-6, vascular endothelial growth factor-A and tumor necrosis factor-alpha in the peritoneal environment at the three healthy, endometriotic and post-treatment milestones.

Twenty-two 8-week-old Sprague–Dawley rats with normal estrus cycles were recruited in a prospective, parallel-group, placebo-controlled, double-blind, stratified-randomized animal trial with the equal allocation ratio of 1:1 challenging the efficacy of levamisole. Endometriosis was induced. After 6 weeks, laparotomy was performed to randomly excise one implant for histopathology assessment. Based on the results, they were stratified randomized and allocated (by software) to two groups of nine: levamisole (5 mg/rat/day) or placebo. After 6 weeks, necropsy was done. Two days before each laparotomy, blood samples and during the procedure, peritoneal wash were collected for ELISA.

Seven rats showed success in treatment in the levamisole group, while three did in the other group. The histopathology results descriptively revealed a drop in the levamisole group, which was not meaningful statistically (0.66 ± 1.32 vs. 2.00 ± 1.50, p = 0.065). The comparisons of the post-treatment leukocytes and lymphocytes in the groups showed significant differences (11088.88 ± 5869.50 vs. 4677.77 ± 3476.98, p = 0.008, and 8588.88 ± 5721.32 vs. 3511.11 ± 2835.24, p = 0.014, respectively). The results of the cytokines were mostly, but not completely, in favor of the efficacy of levamisole.

This study indicates a possible successful role for levamisole in the treatment of experimental endometriosis. Further studies to assess the effects of high dose levamisole on endometriosis are recommended. Similar content being viewed by others

Berkkanoglu M, Arici A (2003) Immunology and endometriosis. Am J Reprod Immunol 50(1):48–59. doi:10.1034/j.1600-0897.2003.00042.x Murphy AA (2002) Clinical aspects of endometriosis. Ann N Y Acad Sci 955:1–10 (discussion 34–16, 396–406) Eskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24(2):235–258 Vignali M, Infantino M, Matrone R, Chiodo I, Somigliana E, Busacca M, Vigano P (2002) Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril 78(4):665–678 Busacca M, Fedele L, Bianchi S, Candiani M, Agnoli B, Raffaelli R, Vignali M (1998) Surgical treatment of recurrent endometriosis: laparotomy versus laparoscopy. Hum Reprod 13(8):2271–2274 Herington JL, Bruner-Tran KL, Lucas JA, Osteen KG (2011) Immune interactions in endometriosis. Expert Rev Clin Immunol 7(5):611–626. doi:10.1586/eci.11.53 Ulukus M, Arici A (2005) Immunology of endometriosis. Minerva Ginecol 57(3):237–248 Osuga Y, Koga K, Hirota Y, Hirata T, Yoshino O, Taketani Y (2011) Lymphocytes in endometriosis. Am J Reprod Immunol 65(1):1–10. doi:10.1111/j.1600-0897.2010.00887.x Seli E, Berkkanoglu M, Arici A (2003) Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 30(1):41–61 van der Linden PJ (1996) Theories on the pathogenesis of endometriosis. Hum Reprod 11(Suppl 3):53–65 Soares SR, Martinez-Varea A, Hidalgo-Mora JJ, Pellicer A (2012) Pharmacologic therapies in endometriosis: a systematic review. Fertil Steril 98(3):529–555. doi:10.1016/j.fertnstert.2012.07.1120 Naylor PH, Hadden JW (2003) T cell targeted immune enhancement yields effective T cell adjuvants. Int Immunopharmacol 3(8):1205–1215. doi:10.1016/s1567-5769(03)00025-0 Vernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44(5):684–694 Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A (1999) Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 72(1):135–141 Uchiide I, Ihara T, Sugamata M (2002) Pathological evaluation of the rat endometriosis model. Fertil Steril 78(4):782–786. doi:10.1016/s0015-0282(02)03327-7 Matarese G, De Placido G, Nikas Y, Alviggi C (2003) Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends Mol Med 9(5):223–228 Signorile PG, Baldi A (2010) Endometriosis: new concepts in the pathogenesis. Int J Biochem Cell Biol 42(6):778–780. doi:10.1016/j.biocel.2010.03.008 Berbic M, Fraser IS (2011) Regulatory T cells and other leukocytes in the pathogenesis of endometriosis. J Reprod Immunol 88(2):149–155. doi:10.1016/j.jri.2010.11.004 Symoens J, Veys E, Mielants M, Pinals R (1978) Adverse reactions to levamisole. Cancer Treat Rep 62(11):1721–1730 Ocal G, Kokcu A, Cetinkaya MB, Tosun M, Kefeli M, Kandemir B (2007) Efficacy of levamisole on experimental endometriosis. Int J Gynaecol Obstet 99(1):38–42. doi:10.1016/j.ijgo.2007.04.041 Acknowledgments The authors would like to express their gratitude to Dr. Behzad Haddad for his help in the editing of images, Dr. Zahra Nikoo for her assistance in the surgical procedures and the funders of this study. Budget was received for this research from Laparoscopy Research Center, Infertility Research Center and Administration of Research of Shiraz University of Medical Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of interest None. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Azimirad, A., Alborzi, S., Kumar, P.V. et al. The effects of levamisole on experimental endometriosis: a randomized controlled trial in a rat model. Arch Gynecol Obstet 288, 1301–1308 (2013). https://doi.org/10.1007/s00404-013-2895-8 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00404-013-2895-8